Jubilant Therapeutics Inc., a subsidiary of Jubilant Life Sciences Ltd., is a U.S based innovative biopharmaceutical company developing breakthrough therapies for treating unmet medical need in serious diseases such as cancer.
Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and other businesses including Drug Discovery Solutions, India Branded Pharmaceuticals and Proprietary Innovation. For more info: www.jubl.com
Jubilant Life Sciences Announces Appointment of Dr. Syed Kazmi as President and CEO of its New Innovative Biopharmaceutical Company in the U.S. – Jubilant Therapeutics Inc.
Yardley, PA, United States; Sep 09, 2019
Jubilant Life Sciences Limited has announced that Dr. Syed Kazmi, PhD, MBA, will join its new innovative biopharmaceutical company in the U.S., Jubilant Therapeutics Inc., as President and Chief Executive Officer.
Dr. Kazmi joins from Novartis Pharmaceuticals Corporation where he was Vice President, Global Head of Business Development & Licensing for Oncology.
Jubilant Therapeutics is a capital efficient, semi-virtual biopharma with agile business model and asset specific subsidiaries for creative partnerships. The company’s core strategy is to develop novel and targeted small molecule therapies primarily in the area of Oncology and Auto-Immune disorders.
Jubilant Therapeutics plans to work on a portfolio of new chemical entities and fast track promising assets from discovery phase into development phase (Clinical POC) by leveraging key strengths:
|Lead Programs, Indication
|BRD4, Liquid and solid tumors, Epigenetics||Pre-clinical||Partnered with Checkpoint Therapeutics at lead stage with potential milestones of $180m. Successfully completed toxicology studies with expected progress to Phase I clinical trials near-term.|
|LSD1/HDAC6 –Dual Inhibitor, MDS/AML, Epigenetics||Pre-clinical||Novel dual first in class epigenetic inhibitors of LSD1/HDAC6 to address unmet needs in liquid cancers like acute myeloid leukemia (AML).|
|PDL-1, Broad spectrum of Cancer, Immuno-Oncology||Lead optimisation||Small molecule therapy with comparable efficacy to large molecules with lower side effects.Complete lead optimisation near-term.|
|PAD4, Inflammation and auto immune disorder, Epigenetics||Lead optimisation||Potential to address unmet needs in multiple auto-immune disorders like rheumatoid arthritis, psoriasis etc. Preclinical candidate nomination near-term.|
|PRMT5, Lymphoma, Epigenetics||Lead identification||Complete lead identification near-term.|
790 Township Line Road, Suite 175 Yardley,
PA 19067, USA
Tel: +1 215 550 2810
#96, Industrial Suburb 2nd Stage, Yeshwantpur Bengaluru - 560 022 Karnataka India.
Tel. : +91 80 66628400, 66628250